Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 9/20 | 0.59 |
| ▸ | HMGCR | P04035 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30212080 | 0.92 | FASN (0.66) | FASNHMGCRMEN1KMT2APAK1 | |
| SCHEMBL30212085 | 0.88 | FASN (0.66) | FASNHMGCRMEN1KMT2APAK1 | |
| SCHEMBL29387296 | 0.86 | FASN (0.59) | FASNHMGCRMEN1KMT2APAK1 | |
| SCHEMBL30212066 | 0.80 | FASN (0.72) | FASN | |
| SCHEMBL30212065 | 0.80 | FASN (0.72) | FASN | |
| Desaspidin SCHEMBL29613713 | 0.76 | FASN (0.51) | FASNHMGCRMEN1KMT2APAK1 | |
| Desaspidin SCHEMBL2732746 | 0.76 | FASN (0.51) | FASNHMGCRMEN1KMT2APAK1 | |
| SCHEMBL30212088 | 0.76 | FASN (0.72) | FASN | |
| SCHEMBL30212090 | 0.75 | FASN (1.00) | FASNMEN1KMT2A | |
| SCHEMBL30212107 | 0.74 | FASN (0.77) | FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12178790-B2 | Antibacterial compound isolated from Psiloxylon mauritianum and its derivatives | SORRES, Jonathan (FR) | 2024-12-31 | — | — | US | disclosed |
| US-20230062900-A1 | NEW ANTIBACTERIAL COMPOUND ISOLATED FROM PSILOXYLON MAURITIANUM AND ITS DERIVATIVES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062900-A1 | NEW ANTIBACTERIAL COMPOUND ISOLATED FROM PSILOXYLON MAURITIANUM AND ITS DERIVATIVES | PNN, AAAS, MRPS35 | FASN 37/4885HMGCR 2105/4885MEN1 2121/4885 |
| US-12178790-B2 | Antibacterial compound isolated from Psiloxylon mauritianum and its derivatives | AAAS, PNN, MRPL9 | FASN 27/4885HMGCR 2026/4885MEN1 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.